DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

SURMOUNT-1 trial results

Adults with overweight or obesity without diabetes.

Mounjaro
Phase
Phase 3
Follow-up
72 weeks
Randomised
2,539
Sponsor
Eli Lilly
Publication
New England Journal of Medicine · 2022

Double-blind, placebo-controlled. Treatment-regimen analysis.

Mean body weight change at 72 weeks
  • Tirzepatide 5 mg−15.0%
  • Tirzepatide 10 mg−19.5%
  • Tirzepatide 15 mg−20.9%
  • Placebo−3.1%
Mean body weight change at 72 weeks
Trial armResult
Tirzepatide 5 mg−15.0%
Tirzepatide 10 mg−19.5%
Tirzepatide 15 mg−20.9%
Placebo−3.1%
Participants who lost at least 5% of body weight at week 72
Trial armResult
Tirzepatide 5 mg85.1%
Tirzepatide 10 mg88.9%
Tirzepatide 15 mg90.9%
Placebo34.5%
Stopped treatment due to adverse events
Trial armResult
Tirzepatide 5 mg4.3%
Tirzepatide 10 mg7.1%
Tirzepatide 15 mg6.2%
Placebo2.6%

Safety. Adverse events led 4.3%, 7.1% and 6.2% of the respective tirzepatide groups and 2.6% of the placebo group to stop treatment.

Published paper PubMed abstract NCT04184622